Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 25;10(4):347.
doi: 10.3390/antibiotics10040347.

Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review

Marta Mejías-Trueba  1 , Marta Alonso-Moreno  1 , Laura Herrera-Hidalgo  2 , Maria Victoria Gil-Navarro  2
Affiliations
Review

Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review

Marta Mejías-Trueba et al. Antibiotics (Basel). .

Abstract

Vancomycin is commonly used as a treatment for neonatal infections. However, there is a lack of consensus establishing the optimal vancomycin therapeutic regimen and defining the most appropriate PK/PD parameter correlated with the efficacy. A recent guideline recommends AUC-guided therapeutic dosing in treating serious infections in neonates. However, in clinical practice, trough serum concentrations are commonly used as a surrogate PKPD index for AUC24. Despite this, target serum concentrations in a neonatal population remain poorly defined. The objective is to describe the relationship between therapeutic regimens and the achievement of clinical or pharmacokinetic outcomes in the neonatal population. The review was carried out following PRISMA guidelines. A bibliographic search was manually performed for studies published on PubMed and EMBASE. Clinical efficacy and/or target attainment and the safety of vancomycin treatment were evaluated through obtaining serum concentrations. A total of 476 articles were identified, of which 20 met the inclusion criteria. All of them evaluated the target attainment, but only two assessed the clinical efficacy. The enormous variability concerning target serum concentrations is noteworthy, which translates into a difficulty in determining which therapeutic regimen achieves the best results. Moreover, there are few studies that analyze clinical efficacy results obtained after reaching predefined trough serum concentrations, this information being essential for clinical practice.

Keywords: clinical efficacy; neonates; review; target attainment; vancomycin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study selection flowchart.
See this image and copyright information in PMC

References

    1. Tan W.-H., Brown N., Kelsall A.W., McClure R.J. Dose regimen for vancomycin not needing serum peak levels? Arch. Dis. Child. Fetal Neonatal Ed. 2002;87:214–216. doi: 10.1136/fn.87.3.F214. - DOI - PMC - PubMed
    1. Gwee A., Cranswick N., Donath S.M., Hunt R., Curtis N. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial. BMJ Open. 2018;8:e022603. doi: 10.1136/bmjopen-2018-022603. - DOI - PMC - PubMed
    1. Germovsek E., Osborne L., Gunaratnam F., A Lounis S., Busquets F.B., Standing J.F., Sinha A.K. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. J. Antimicrob. Chemother. 2019;74:1003–1011. doi: 10.1093/jac/dky525. - DOI - PubMed
    1. Murphy J.E. Clinical Pharmacokinetics. 6th ed. American Society of Health–System Pharmacists; Bethesda, MD, USA: 2016.
    1. Kearns G.L., Abdel–Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 2003;349:1157–1167. doi: 10.1056/NEJMra035092. - DOI - PubMed